HomeDBVT • NASDAQ
DBV Technologies SA - ADR
Follow
$0.85
Pre-market: $0.81
Closed: Mar 7, 9:09:34 AM GMT-5 · USD · NASDAQ · Disclaimer
Key events shows relevant news articles on days with large price movements Key events shows relevant news articles on days with large price movements Key events shows relevant news articles on days with large price movements
Seres Therapeutics Inc
$1.01
MCRB0.00%
Denali Therapeutics Inc
$20.52
DNLI0.34%
Prelude Therapeutics Inc
$4.17
PRLD0.48%
Cidara Therapeutics Inc
$0.70
CDTX0.086%
Bicycle Therapeutics PLC
$24.64
BCYC0.081%
ROIV
$11.57
ROIV0.00%
Immunovant Inc
$33.06
IMVT0.00%
Veru Inc
$0.64
VERU0.00%
Citius Pharmaceuticals Inc
$0.72
CTXR0.00%
Ideaya Biosciences Inc
$46.36
IDYA0.00%
Financials
Income Statement
Revenue Net income Fiscal Q3 2023 ended 9/30/23. Reported on 10/31/23. Revenue The total amount of income generated by the sale of goods or services related to the company's primary operations Operating expense Represents the total incurred expenses through normal operations Net income Company’s earnings for a period net of operating costs, taxes, and interest Net profit margin Measures how much net income or profit is generated as a percentage of revenue. Earnings per share Represents the company's profit divided by the outstanding shares of its common stock. EBITDA Earnings before interest, taxes, depreciation, and amortization, is a measure of a company's overall financial performance and is used as an alternative to net income in some circ*mstances Effective tax rate The percent of their income that a corporation pays in taxes(USD) Sep 2023info Y/Y change 2.37M 14.37% 20.64M 2.73% -16.74M 3.19% -705.56 15.35% -0.16 — -17.67M -0.19% — —
Balance Sheet
Total assets Total liabilities Fiscal Q3 2023 ended 9/30/23. Reported on 10/31/23. Cash and short-term investments Investments that are relatively liquid and have maturities between 3 months and one year Total assets The total amount of assets owned by a company Total liabilities Sum of the combined debts a company owes Total equity The value of subtracting the total liabilities from the total assets of a company Shares outstanding Total number of common shares outstanding as of the latest date disclosed in a financial filing Price to book A ratio used to determine if a company’s market value is in line with the value of its assets less liabilities and preferred stock Return on assets A financial ratio that shows a company’s profitability compared to its assets Return on capital Company’s return above the average cost it pays for its debt and equity capital(USD) Sep 2023info Y/Y change 149.14M -29.87% 189.78M -23.51% 45.79M 26.97% 143.99M — 96.11M — 0.57 — -22.43% — -29.28% —
Cash Flow
Net change in cash Fiscal Q3 2023 ended 9/30/23. Reported on 10/31/23. Net income Company’s earnings for a period net of operating costs, taxes, and interest Cash from operations Net cash used or generated for core business activities Cash from investing Net cash used or generated in investing activities such as purchasing assets Cash from financing Net cash used or generated in financing activities such as dividend payments and loans Net change in cash The amount by which a company's cash balance increases or decreases in an accounting period Free cash flow Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments(USD) Sep 2023info Y/Y change -16.74M 3.19% -19.57M 2.37% -322.00K -311.84% -837.00K -2.32% -24.83M 29.67% -13.63M -3.97%
US listed security Listed on NASDAQ
Previous close The last closing price
$0.85
Year range The range between the high and low prices over the past 52 weeks
$0.65 - $2.37
Market cap A valuation method that multiplies the price of a company's stock by the total number of outstanding shares.
149.90M USD
Avg Volume The average number of shares traded each day over the past 30 days
57.74K
About
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration. Wikipedia Founded Mar 29, 2002 Website Employees 97
Discover more
You may be interested in
info This list is generated from recent searches, followed securities, and other activity. Learn more All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
People also search for
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
HelpSend feedbackPrivacyTermsDisclaimer